ATC Group: L03AA13 Pegfilgrastim

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of L03AA13 in the ATC hierarchy

Level	Code	Title
`1`	L	Antineoplastic and immunomodulating agents
`2`	L03	Immunostimulants
`3`	L03A	Immunostimulants
`4`	L03AA	Colony stimulating factors
`5`	L03AA13	Pegfilgrastim

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Code	Route	Amount	Notes
PAREN	Parenteral	0.3 mg

Active ingredients in L03AA13

Active Ingredient
Pegfilgrastim
Pegfilgrastim is a sustained duration form of filgrastim due to decreased renal clearance. Pegfilgrastim and filgrastim have been shown to have identical modes of action, causing a marked increase in peripheral blood neutrophil counts within 24 hours, with minor increases in monocytes and/or lymphocytes.

Related product monographs

Document	Type	Information Source
FULPHILA Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)
NEULASTIM Solution for injection	MPI, Generic	Health Products Regulatory Authority (ZA)
NYVEPRIA Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)
PELMEG Solution for injection	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)
STIMUFEND Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)
UDENYCA Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)